

Appendix 3X

Initial Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	SUDA Pharmaceuticals Ltd
ABN	35 090 987 250

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Paul Hopper
Date of appointment	15 May 2019

Part 1 - Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities
NIL

Appendix 3X
Initial Director's Interest Notice

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest	Number & class of Securities
<p>Note: Provide details of the circumstances giving rise to the relevant interest.</p> <p>N/A</p>	

Part 3 – Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	15 May 2019, as part of the Company's Employee Share Option Plan.
Nature of interest	Subject to shareholder approval, the right to be issued the securities set out below.
Name of registered holder (if issued securities)	Director related entity
No. and class of securities to which interest relates	<p>13,000,000 unlisted options exercisable at \$0.0059, expiring: 14 May 2023</p> <p>13,000,000 unlisted options exercisable at \$0.0063, vesting after 14 May 2020 and expiring: 14 May 2023</p> <p>14,000,000 unlisted options exercisable at \$0.0067, vesting after 14 May 2021 and expiring: 14 May 2023</p>

+ See chapter 19 for defined terms.